| A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (NCT06097364) | Regeneron Pharmaceuticals | 2023-11-14 |
| An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant (NCT05106387) | Regeneron Pharmaceuticals | 2023-10-19 |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma (NCT05730036) | Regeneron Pharmaceuticals | 2023-09-18 |
| A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer (NCT05800015) | Regeneron Pharmaceuticals | 2023-08-08 |
| A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants (NCT05970718) | Regeneron Pharmaceuticals | 2023-08-07 |
| A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT05785767) | Regeneron Pharmaceuticals | 2023-06-30 |
| A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP) (NCT06064656) | Regeneron Pharmaceuticals | 2023-06-29 |
| A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations (NCT05788536) | Regeneron Pharmaceuticals | 2023-06-27 |
| A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants (NCT05618808) | Regeneron Pharmaceuticals | 2023-05-24 |
| A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have (NCT05831176) | Regeneron Pharmaceuticals | 2023-05-03 |
| A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas (NCT05685173) | Regeneron Pharmaceuticals | 2023-04-20 |
| A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works (NCT05744921) | Regeneron Pharmaceuticals | 2023-03-07 |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition (NCT05519475) | Regeneron Pharmaceuticals | 2023-02-09 |
| A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab (NCT05259709) | Regeneron Pharmaceuticals | 2023-02-07 |
| A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery (NCT05608291) | Regeneron Pharmaceuticals | 2023-01-16 |
| A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants (NCT05603195) | Regeneron Pharmaceuticals | 2023-01-12 |
| Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial (NCT05590585) | Regeneron Pharmaceuticals | 2023-01-11 |
| Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (NCT05673967) | Regeneron Pharmaceuticals | 2023-01-09 |
| Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants (NCT05546957) | Regeneron Pharmaceuticals | 2023-01-05 |
| A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (NCT05394116) | Regeneron Pharmaceuticals | 2022-11-21 |
| An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (NCT05363319) | Regeneron Pharmaceuticals | 2022-10-26 |
| A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants (NCT05481333) | Regeneron Pharmaceuticals | 2022-10-24 |
| Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT05131204) | Regeneron Pharmaceuticals | 2022-10-06 |
| A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022 (NCT05791695) | Regeneron Pharmaceuticals | 2022-09-16 |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments (NCT05137054) | Regeneron Pharmaceuticals | 2022-08-17 |
| Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants (NCT05430919) | Regeneron Pharmaceuticals | 2022-08-15 |
| A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA) (NCT05092347) | Regeneron Pharmaceuticals | 2022-08-02 |
| Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672) | Regeneron Pharmaceuticals | 2022-07-14 |
| REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure (NCT05353166) | Regeneron Pharmaceuticals | 2022-06-30 |
| Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma (NCT05338879) | Regeneron Pharmaceuticals | 2022-06-22 |
| Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT05338892) | Regeneron Pharmaceuticals | 2022-06-22 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants (NCT05291546) | Regeneron Pharmaceuticals | 2022-04-13 |
| Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19 (NCT05293678) | Regeneron Pharmaceuticals | 2022-04-12 |
| A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) (NCT05088460) | Regeneron Pharmaceuticals | 2022-02-28 |
| Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (NCT05203380) | Regeneron Pharmaceuticals | 2022-01-27 |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (NCT05169489) | Regeneron Pharmaceuticals | 2022-01-24 |
| COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers (NCT05181683) | Regeneron Pharmaceuticals | 2022-01-07 |
| COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19 (NCT05092581) | Regeneron Pharmaceuticals | 2021-12-16 |
| A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis (NCT05070858) | Regeneron Pharmaceuticals | 2021-12-14 |
| Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH) (NCT05423327) | Regeneron Pharmaceuticals | 2021-12-09 |
| A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (NCT04916002) | Regeneron Pharmaceuticals | 2021-11-30 |
| A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer (NCT05125016) | Regeneron Pharmaceuticals | 2021-11-30 |
| Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer (NCT04982224) | Regeneron Pharmaceuticals | 2021-11-09 |
| COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease (NCT05081388) | Regeneron Pharmaceuticals | 2021-11-08 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers (NCT05102136) | Regeneron Pharmaceuticals | 2021-10-27 |
| A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults (NCT05074433) | Regeneron Pharmaceuticals | 2021-10-25 |
| Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) (NCT04577820) | Regeneron Pharmaceuticals | 2021-10-13 |
| Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) (NCT04959448) | Regeneron Pharmaceuticals | 2021-08-12 |
| A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers (NCT04940364) | Regeneron Pharmaceuticals | 2021-08-04 |
| Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy (NCT04811716) | Regeneron Pharmaceuticals | 2021-07-29 |
| Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy (NCT04888507) | Regeneron Pharmaceuticals | 2021-07-08 |
| Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy (NCT04646005) | Regeneron Pharmaceuticals | 2021-06-28 |
| COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers (NCT04852978) | Regeneron Pharmaceuticals | 2021-04-29 |
| A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) (NCT04417894) | Regeneron Pharmaceuticals | 2021-04-14 |
| CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma (NCT04698187) | Regeneron Pharmaceuticals | 2021-03-11 |
| Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis (NCT04287608) | Regeneron Pharmaceuticals | 2021-03-10 |
| CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (NCT04695977) | Regeneron Pharmaceuticals | 2021-02-24 |
| Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next) (NCT04515524) | Regeneron Pharmaceuticals | 2021-02-05 |
| CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT04633278) | Regeneron Pharmaceuticals | 2021-01-21 |
| Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis (NCT04709575) | Regeneron Pharmaceuticals | 2021-01-14 |
| REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy (NCT04409080) | Regeneron Pharmaceuticals | 2021-01-13 |
| COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection (NCT04666441) | Regeneron Pharmaceuticals | 2020-12-15 |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab (NCT04590326) | Regeneron Pharmaceuticals | 2020-12-08 |
| Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers (NCT04616079) | Regeneron Pharmaceuticals | 2020-11-19 |
| Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers (NCT04616105) | Regeneron Pharmaceuticals | 2020-11-18 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers (NCT04601844) | Regeneron Pharmaceuticals | 2020-11-16 |
| Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma (NCT04373083) | Regeneron Pharmaceuticals | 2020-11-15 |
| T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge (NCT04614571) | Regeneron Pharmaceuticals | 2020-11-02 |
| A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid (NCT04206553) | Regeneron Pharmaceuticals | 2020-10-28 |
| Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (NCT04465487) | Regeneron Pharmaceuticals | 2020-10-05 |
| Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) (NCT04442269) | Regeneron Pharmaceuticals | 2020-09-15 |
| Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) (NCT04394351) | Regeneron Pharmaceuticals | 2020-09-01 |
| Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 (NCT04519437) | Regeneron Pharmaceuticals | 2020-07-26 |
| COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay (NCT04452318) | Regeneron Pharmaceuticals | 2020-07-13 |
| Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (NCT04429503) | Regeneron Pharmaceuticals | 2020-06-29 |
| Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia (NCT04233918) | Regeneron Pharmaceuticals | 2020-06-29 |
| Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 (NCT04425629) | Regeneron Pharmaceuticals | 2020-06-16 |
| Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 (NCT04426695) | Regeneron Pharmaceuticals | 2020-06-10 |
| Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 (NCT04315298) | Regeneron Pharmaceuticals | 2020-03-18 |
| Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma (NCT04154943) | Regeneron Pharmaceuticals | 2020-03-10 |
| Registry of Asthma Patients Initiating DUPIXENT® (NCT04287621) | Regeneron Pharmaceuticals | 2020-03-02 |
| Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) (NCT04209634) | Regeneron Pharmaceuticals | 2020-01-27 |
| Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy (NCT04159415) | Regeneron Pharmaceuticals | 2020-01-07 |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer (NCT04077099) | Regeneron Pharmaceuticals | 2020-01-07 |
| REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability. (NCT04162470) | Regeneron Pharmaceuticals | 2019-12-03 |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies (NCT03888105) | Regeneron Pharmaceuticals | 2019-11-13 |
| Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration (NCT04126317) | Regeneron Pharmaceuticals | 2019-11-04 |
| An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD) (NCT03936335) | Regeneron Pharmaceuticals | 2019-09-30 |
| First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) (NCT04083534) | Regeneron Pharmaceuticals | 2019-09-26 |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors (NCT03972657) | Regeneron Pharmaceuticals | 2019-08-12 |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients (NCT03916627) | Regeneron Pharmaceuticals | 2019-07-23 |
| CemiplimAb Survivorship Epidemiology (NCT03836105) | Regeneron Pharmaceuticals | 2019-06-27 |
| Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma (NCT03969004) | Regeneron Pharmaceuticals | 2019-06-04 |
| Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants (NCT03969849) | Regeneron Pharmaceuticals | 2019-06-03 |
| A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee (NCT03956550) | Regeneron Pharmaceuticals | 2019-05-21 |
| Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (NCT03946748) | Regeneron Pharmaceuticals | 2019-05-16 |
| Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma (NCT03889912) | Regeneron Pharmaceuticals | 2019-04-11 |
| Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip (NCT03949673) | Regeneron Pharmaceuticals | 2019-04-08 |
| Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy (NCT03793608) | Regeneron Pharmaceuticals | 2019-03-12 |
| Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis (NCT03710941) | Regeneron Pharmaceuticals | 2019-02-19 |